Meet The Professors: Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Sonali M Smith, MD

Track 1: Appropriate management of molecular subtypes of diffuse large B-cell lymphoma (DLBCL); challenges in improving outcomes with the addition of novel agents to front-line R-CHOP
Track 2: Smart Start study: Final results with a rituximab/lenalidomide/ibrutinib lead-in before the combination with chemotherapy for patients with newly diagnosed DLBCL
Track 3: Importance of the interval between diagnosis and treatment for newly diagnosed DLBCL and implications for bias in clinical trials
Track 4: Risk of relapse with germinal center versus non-germinal center subtypes of DLBCL
Track 5: Activity and tolerability of the recently FDA-approved anti-CD79b antibody-drug conjugate polatuzumab vedotin in combination with bendamustine/rituximab (BR) for relapsed/refractory (R/R) DLBCL
Track 6: Activity of single-agent polatuzumab vedotin in patients with R/R DLBCL; integration of polatuzumab vedotin/BR into clinical practice
Track 7: Therapeutic options and investigational approaches for R/R DLBCL
Track 8: POLARIX: An ongoing Phase III trial comparing polatuzumab vedotin with R-CHP to R-CHOP for patients with previously untreated DLBCL
Track 9: Variations in chimeric antigen receptor (CAR) T-cell constructs; activity and tolerability of different CAR T-cell therapy products for R/R DLBCL
Track 10: Integration of CAR T-cell therapy into the treatment algorithm for R/R DLBCL
Track 11: Neurologic toxicity and cytokine release syndrome associated with CAR T-cell therapy
Track 12: Selection and sequencing of therapy for patients with R/R mantle cell lymphoma (MCL)
Track 13: Drug activity and tolerability and patient quality of life with ibrutinib compared to acalabrutinib
Track 14: Results of the Phase III ECOG-E1912 trial evaluating up-front ibrutinib/rituximab versus FCR (fludarabine/cyclophosphamide/rituximab) for younger patients with chronic lymphocytic leukemia (CLL)
Track 15: Alliance A041202 trial: Efficacy and tolerability of ibrutinib alone or in combination with either rituximab or BR for older patients with untreated CLL
Track 16: Response rates and duration of minimal residual disease (MRD) negativity with limited-duration nonchemotherapy combination regimens for previously untreated CLL
Track 17: Risk assessment, prevention and management of venetoclax-associated tumor lysis syndrome
Track 18: Activity and tolerability of acalabrutinib alone or in combination with obinutuzumab for CLL
Track 19: Second- and third-line therapy options for patients with CLL
Track 20: Perspective on the results of the Phase III RELEVANCE trial: Lenalidomide/rituximab (R2) versus rituximab/chemotherapy, each followed by maintenance rituximab, for patients with newly diagnosed follicular lymphoma (FL)
Track 21: Available data with and current clinical role of R2 for patients with R/R FL
Track 22: Comparison of the activity and side-effect profiles of approved and investigational PI3 kinase inhibitors for R/R FL
Track 23: Approach to choosing among brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (AVD), standard AVD/bleomycin (ABVD) and response-adapted ABVD as first-line therapy for advanced classical Hodgkin lymphoma
Track 24: Activity of brentuximab vedotin alone or in combination with nivolumab in patients with R/R Hodgkin lymphoma

Noopur Raje, MD

Track 1: Updated risk-stratification model incorporating the revised IMWG diagnostic criteria for smoldering multiple myeloma (MM)
Track 2: Role of imaging in the monitoring and management of MM
Track 3: Perspective on the progression-free survival improvement with lenalidomide compared to observation alone for patients with asymptomatic high-risk smoldering MM treated on the Phase III ECOG-E3A06 trial
Track 4: Results of the Phase III CASSIOPEIA study evaluating the addition of daratumumab to bortezomib/thalidomide/dexamethasone for newly diagnosed MM in patients eligible for autologous stem cell transplant (ASCT)
Track 5: Emerging data from the Phase III MAIA trial evaluating lenalidomide/dexamethasone (Rd) with or without daratumumab for patients with newly diagnosed MM who are not candidates for ASCT
Track 6: Role of MRD assessment in clinical decision-making
Track 7: Results of the Phase III FORTE trial: Efficacy of carfilzomib/Rd (KRd) with or without ASCT for newly diagnosed MM according to risk status
Track 8: Status of the ongoing Phase III ECOG-E1A11 (ENDURANCE) trial: Bortezomib/Rd versus KRd followed by limited or indefinite maintenance lenalidomide for symptomatic newly diagnosed MM
Track 9: Clinical experience with and mitigation of differing side effects of bortezomib and carfilzomib
Track 10: Appropriate use of oral ixazomib as maintenance therapy after ASCT
Track 11: Dose, duration and tolerability of maintenance lenalidomide
Track 12: Therapeutic options for patients with MM experiencing disease relapse on maintenance lenalidomide
Track 13: COLUMBA trial: Efficacy and safety of subcutaneous versus intravenous administration of daratumumab for patients with R/R MM
Track 14: Similarities and differences between the anti-CD38 antibodies daratumumab and isatuximab
Track 15: Melflufen: Novel mechanism of action and structural comparison to standard melphalan
Track 16: Overexpression of Bcl-2 in patients with t(11;14) MM and rationale for the use of venetoclax
Track 17: Activity and tolerability of anti-B-cell maturation antigen (BCMA) CAR T-cell therapy in patients with MM
Track 18: Use of a bispecific T-cell engager to target BCMA and CD3 in patients with MM; early efficacy and safety data with AMG 420
Track 19: Incidence and management of cytokine release syndrome and neurotoxicity associated with anti-BCMA CAR T-cell therapy for MM
Track 20: Future directions for CAR T-cell therapy in MM
Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois
Neil Love, MD
Research To Practice
Miami, Florida